Drug Profile
RVT 2001
Alternative Names: H3B-8800; RVT-2001Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator H3 Biomedicine
- Developer Eisai Inc; H3 Biomedicine
- Class Antineoplastics; Small molecules
- Mechanism of Action SF3B1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Most Recent Events
- 13 Feb 2024 Discontinued - Phase-I for Acute myeloid leukaemia in Taiwan, South Korea, Italy, Belgium, Germany, Spain, France, USA (PO)
- 13 Feb 2024 Discontinued - Phase-I for Chronic myelomonocytic leukaemia in Taiwan, South Korea, Italy, Belgium, Germany, Spain, USA, France (PO)
- 13 Feb 2024 Discontinued - Phase-I for Myelodysplastic syndromes in South Korea, Taiwan, Italy, Belgium, Germany, Spain, France (PO)